Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.

Perwitasari O, Yan X, Johnson S, White C, Brooks P, Tompkins SM, Tripp RA.

Antimicrob Agents Chemother. 2013 Jan;57(1):475-83. doi: 10.1128/AAC.01532-12. Epub 2012 Nov 5.

2.

Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.

Yu J, Wang D, Jin J, Xu J, Li M, Wang H, Dou J, Zhou C.

Antiviral Res. 2016 Mar;127:68-78. doi: 10.1016/j.antiviral.2016.01.011. Epub 2016 Jan 21.

PMID:
26802558
3.

Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses.

Kumar N, Sharma NR, Ly H, Parslow TG, Liang Y.

Antimicrob Agents Chemother. 2011 Dec;55(12):5553-9. doi: 10.1128/AAC.00725-11. Epub 2011 Sep 19.

4.

Germacrone inhibits early stages of influenza virus infection.

Liao Q, Qian Z, Liu R, An L, Chen X.

Antiviral Res. 2013 Dec;100(3):578-88. doi: 10.1016/j.antiviral.2013.09.021. Epub 2013 Oct 3.

PMID:
24095670
5.

In vitro evaluation of synergistic inhibitory effects of neuraminidase inhibitors and methylglyoxal against influenza virus infection.

Charyasriwong S, Watanabe K, Rahmasari R, Matsunaga A, Haruyama T, Kobayashi N.

Arch Med Res. 2015 Jan;46(1):8-16. doi: 10.1016/j.arcmed.2014.12.002. Epub 2014 Dec 15.

PMID:
25523147
6.

Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.

Haasbach E, Pauli EK, Spranger R, Mitzner D, Schubert U, Kircheis R, Planz O.

Antiviral Res. 2011 Sep;91(3):304-13. doi: 10.1016/j.antiviral.2011.07.006. Epub 2011 Jul 13.

PMID:
21777621
7.

The effect of rosuvastatin in a murine model of influenza A infection.

Radigan KA, Urich D, Misharin AV, Chiarella SE, Soberanes S, Gonzalez A, Perlman H, Wunderink RG, Budinger GR, Mutlu GM.

PLoS One. 2012;7(4):e35788. doi: 10.1371/journal.pone.0035788. Epub 2012 Apr 20.

8.

Identification of small molecules that interfere with H1N1 influenza A viral replication.

Bottini A, De SK, Baaten BJ, Wu B, Barile E, Soonthornvacharin S, Stebbins JL, Bradley LM, Chanda SK, Pellecchia M.

ChemMedChem. 2012 Dec;7(12):2227-35. doi: 10.1002/cmdc.201200453. Epub 2012 Nov 8.

9.

Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry.

Wu W, Li R, Li X, He J, Jiang S, Liu S, Yang J.

Viruses. 2015 Dec 25;8(1). pii: E6. doi: 10.3390/v8010006.

10.

[Effect of Panavir on influenza A virus reproduction].

Prokudina EN, Galegov GA, Semenova NP, Grigor'eva TA, Kalinina TS, Litvin AA, Stovbun SV, Sergienko VI.

Antibiot Khimioter. 2006;51(6):7-10. Russian.

PMID:
17523415
11.

Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase.

Ding Y, Dou J, Teng Z, Yu J, Wang T, Lu N, Wang H, Zhou C.

Arch Virol. 2014 Dec;159(12):3269-78. doi: 10.1007/s00705-014-2192-2. Epub 2014 Jul 31.

PMID:
25078390
12.

Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus.

Lejal N, Tarus B, Bouguyon E, Chenavas S, Bertho N, Delmas B, Ruigrok RW, Di Primo C, Slama-Schwok A.

Antimicrob Agents Chemother. 2013 May;57(5):2231-42. doi: 10.1128/AAC.02335-12. Epub 2013 Mar 4.

13.

Antiviral activity of novel oseltamivir derivatives against some influenza virus strains.

Kocik J, Kołodziej M, Joniec J, Kwiatek M, Bartoszcze M.

Acta Biochim Pol. 2014;61(3):509-13. Epub 2014 Sep 12.

14.

Discovery of novel benzoquinazolinones and thiazoloimidazoles, inhibitors of influenza H5N1 and H1N1 viruses, from a cell-based high-throughput screen.

Maddry JA, Chen X, Jonsson CB, Ananthan S, Hobrath J, Smee DF, Noah JW, Noah D, Xu X, Jia F, Maddox C, Sosa MI, White EL, Severson WE.

J Biomol Screen. 2011 Jan;16(1):73-81. doi: 10.1177/1087057110384613. Epub 2010 Nov 8.

PMID:
21059874
15.

In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.

Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL.

Antiviral Res. 2011 Nov;92(2):329-40. doi: 10.1016/j.antiviral.2011.09.001. Epub 2011 Sep 8.

16.

In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate.

Ilyushina NA, Donnelly RP.

Antiviral Res. 2014 Nov;111:112-20. doi: 10.1016/j.antiviral.2014.09.008. Epub 2014 Sep 20.

PMID:
25245230
17.

[In vivo efficacy of Ingavirin against pandemic A (H1N1/09)v influenza virus].

Shishkina LN, Nebol'sin VE, Skarnovich MO, Kabanov AS, Sergeev AA, Erdyneeva UB, Serova OA, Demina OK, Agafonov AP, Stavskiĭ EA, Drozdov IG.

Antibiot Khimioter. 2010;55(5-6):32-5. Russian.

PMID:
21033472
18.

The epidemiology and spread of drug resistant human influenza viruses.

Hurt AC.

Curr Opin Virol. 2014 Oct;8:22-9. doi: 10.1016/j.coviro.2014.04.009. Epub 2014 May 24. Review.

PMID:
24866471
19.

Design, synthesis, and in vitro biological evaluation of novel 6-methyl-7-substituted-7-deaza purine nucleoside analogs as anti-influenza A agents.

Lin C, Sun C, Liu X, Zhou Y, Hussain M, Wan J, Li M, Li X, Jin R, Tu Z, Zhang J.

Antiviral Res. 2016 May;129:13-20. doi: 10.1016/j.antiviral.2016.01.005. Epub 2016 Jan 21.

PMID:
26802557
20.

Phosphatidylglycerol suppresses influenza A virus infection.

Numata M, Kandasamy P, Nagashima Y, Posey J, Hartshorn K, Woodland D, Voelker DR.

Am J Respir Cell Mol Biol. 2012 Apr;46(4):479-87. doi: 10.1165/rcmb.2011-0194OC. Epub 2011 Nov 3.

Supplemental Content

Support Center